Long Non-Coding RNA SNHG6 as a Potential Biomarker for Hepatocellular Carcinoma

Abstract

Long Non-coding RNAs (lncRNAs) refer to all non-protein coding transcripts longer than 200 nucleotides. Their critical roles in different biological pathways have been already well established. Altered expression of lncRNAs can be involved in the cancer initiation and/or progression. Since patients with hepatocellular carcinoma (HCC) are usually diagnosed in late stages, developing diagnostic methods seems to be essential. In this study, the expression levels of different lncRNAs were systematically analysed in different genomic and transcriptome datasets. The analyses showed that SNHG6 is among the lncRNAs with distinctive dysregulation of expression and copy number variation in HCC tumors compared with normal tissues. The results also suggest that the dysregulation of SNHG6 is highly cancer type specific. Through co-occurrence analyses, we found that SNHG6 and its related co-expressed genes on 8q are involved in the structural integrity of ribosome and translation. This comprehensive in silico analysis, provides a resource for investigating SNHG6 in hepatocellular carcinoma and lays the groundwork for design of next researches.

SNHG6 Promotes Tumor Growth via Repression of P21 in Colorectal Cancer

“…An increasing number of studies indicate that diverse ncRNAs play a critical role in malignant transformation [32,33]. SNHG6 is a novel snoRNA host gene [34,35], but its cellular functions are largely unknown. Aberrantly expression of SNHG6 has been detected in hepatocellular carcinoma and gastric cancer [34,36,37].…”

“…SNHG6 is a novel snoRNA host gene [34,35], but its cellular functions are largely unknown. Aberrantly expression of SNHG6 has been detected in hepatocellular carcinoma and gastric cancer [34,36,37]. SNHG6 functions as a competing endogenous RNA to promote cancer progression [34,36] and regulates ZEB1 expression by competitively binding miR-101-3p and interacting with UPF1 in hepatocellular carcinoma [37].…”

“…Aberrantly expression of SNHG6 has been detected in hepatocellular carcinoma and gastric cancer [34,36,37]. SNHG6 functions as a competing endogenous RNA to promote cancer progression [34,36] and regulates ZEB1 expression by competitively binding miR-101-3p and interacting with UPF1 in hepatocellular carcinoma [37]. In addition, SNHG6 is associated with poor prognosis and enhanced tumor growth and epithelial-mesenchymal transition via suppressing p27 and sponging miR-101-3p in gastric cancer [38].…”

Long noncoding RNAs biomarker‐based cancer assessment

“…The main obstacles to the treatment of HCC are early metastasis, high-grade malignancy and lack of any proper biomarker for detection of HCC (Bruix & Sherman, 2011). In different studies, it was shown that many lncRNAs can be used as biomarkers and prognostic factors in HCC (Abbastabar, Sarfi, Golestani, & Khalili, 2018 comparison to the patients whose SNHG-6 was not overexpressed and the survival time was 20 months and 49 months, respectively (Birgani et al, 2017;C. Cao, Zhang, et al, 2017).…”

Prognostic and clinicopathological significance of SNHG6 in human cancers: a meta-analysis

“…For this reason, they are historically speculated as transcriptional noise [5]. Nonetheless, with the in-depth investigation of their mechanisms, mounting evidence has revealed that lncRNAs are involved in numerous physiological and pathological processes, thus affecting transcriptional regulation, cellular scaffold orchestration, protein localization and chromatin modification [6,7]. In particular, mutation or aberrant expression of lncRNAs are closely related to tumorigenesis, tumor invasion and metastasis [8,9], which suggests that lncRNAs acting as tumor suppressors or oncogenes have the potential to be important markers for cancer management.…”